ArticleNature communications2022
Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Programming the Diabetic-Infected Wound Microenvironment With a Smart Hydrogel for Ordered Healing Cascade Restoration.Advanced healthcare materials · 2026Article
- Aptamer-guided upconversion nanoconstructs enable proximity-dependent and precise photodynamic therapy for MRSA-infected wounds.Materials today. Bio · 2026Article
- Construction of a MOF-Based Snap-Top Delivery Nanosystem for Powerful Dual-Responsive Synergistic Colitis Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Perspective Approaches to "Trojan Horse" Strategy Development for Combating Bacterial Pathogens.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Phage-Inspired Artificial Peroxidases with Robust Sub-Nanometer Cluster Sites for Efficient Oral Biofilm Elimination and Dental Caries Prevention.Nano-micro letters · 2026Article
- Ultrasound Controlled-Release Hydrogel Promotes Diabetic Wound Healing via Neuroimmune Modulation and Synergistic ROS Scavenging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Stimuli-responsive, antimicrobial-loaded nanocarriers for oral biofilm control and microbiome restoration.International journal of oral science · 2026Review
- High-entropy alloy Janus artificial enzymes for pH-gated sequential redox therapy of drug-resistant bacterial infection.Nature communications · 2026Article
- Ag-CuO Nanozymes Superior to Commercial Silver-Based Dressings: Synergistic Antibacterial Therapy via PTS-Mediated Starvation and Cuproptosis-Like Death.Research (Washington, D.C.) · 2026Article
- Stimuli-responsive hydrogels based on cascade reactions: a novel strategy to promote the efficient repair of diabetic wounds.Theranostics · 2026Review
- Nanozymes-Armed ProbioticResearch (Washington, D.C.) · 2026Article
- Heteromultivalent Nanogels as Highly Potent Inhibitors of Pseudomonas Aeruginosa.Angewandte Chemie (International ed. in English) · 2025Article
- Ophthalmic formulation of methotrexate: a strategy of using the self-assembled LacAC4A nanoparticles for non-invasive drug delivery to the ocular posterior segment.Drug delivery · 2025Article
- Cu single-atom embedded g-CNature communications · 2025Article
- Supramolecular approaches for the treatment of hypoxic regions in tumours.Nature reviews. Chemistry · 2025Review
- "Double-sided protector" Janus hydrogels for skin and mucosal wound repair: applications, mechanisms, and prospects.Journal of nanobiotechnology · 2025Review
- Antibacterial carbon dots.Materials today. Bio · 2025Review
- Supramolecular discrimination and diagnosis-guided treatment of intracellular bacteria.Nature communications · 2025Article
- Engineered hypoxia-responsive albumin nanoparticles mediating mitophagy regulation for cancer therapy.Nature communications · 2025Article
- Enhancing antibacterial efficacy through macrocyclic host complexation of fluoroquinolone antibiotics for overcoming resistance.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wound is one of the most intractable chronic wounds that is prone to bacterial infection. Hypoxia is an important feature in its microenvironment. However, it is challenging for antimicrobial therapy to directly apply the existing hypoxia-responsive drug delivery systems due to the active targeting deficiency and the biofilm obstacle. Herein, we customizes a hypoxia-responsive carrier, lactose-modified azocalix[4]arene (LacAC4A) with the ability to actively target and inhibit biofilm. By loading ciprofloxacin (Cip), the resultant supramolecular nanoformulation Cip@LacAC4A demonstrates enhanced antibacterial efficacy resulting from both the increased drug accumulation and the controlled release at the site of infection. When applied on diabetic wounds together with multidrug-resistant Pseudomonas aeruginosa infection in vivo, Cip@LacAC4A induces definitely less inflammatory infiltration than free Cip, which translates into high wound healing performance. Importantly, such design principle provides a direction for developing antimicrobial drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.